This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailey, J. E. Articles by Nutt, D. J. Search for Related Content PubMed Articles by Bailey, J. E. Articles by Nutt, D. J. Social Bookmarking                         What's this?

The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man

University of Bristol Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1 TD, UK

John Potokar

University of Bristol Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1 TD, UK

Nick Coupland

University of Bristol Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1 TD, UK

David J. Nutt

University of Bristol Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1 TD, UK

The selective serotonin re-uptake inhibitors (SSRIs) are increasingly being used to treat depression and anxiety disorders. Gastrointestinal (GI) symptoms are the main side effects, probably resulting from the stimulation of central or peripheral 5-HT receptors. The present double-blind, placebo-controlled study was undertaken to see if the GI side effects of fluvoxamine could be attenuated by the co-administration of the 5-HT₃ antagonist ondansetron. The results demonstrate that, in volunteers, a single 100 mg oral dose of fluvoxamine can produce GI symptoms. Co-administration of ondansetron significantly reduced peak nausea and GI side effects, compared with placebo.

Key Words: ondansetron • fluvoxamine • side effects • gastrointestinal symptoms • SSRIs

Journal of Psychopharmacology, Vol. 9, No. 2, 137-141 (1995)
DOI: 10.1177/026988119500900208


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Cukor, S. D. Cohen, R. A. Peterson, and P. L. Kimmel Psychosocial Aspects of Chronic Disease: ESRD as a Paradigmatic Illness J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3042 - 3055. [Abstract] [Full Text] [PDF]

				S. D. Cohen, L. Norris, K. Acquaviva, R. A. Peterson, and P. L. Kimmel Screening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1332 - 1342. [Abstract] [Full Text] [PDF]

				S. J. Wilson, J. E. Bailey, C. Alford, and D. J. Nutt Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers J Psychopharmacol, July 1, 2000; 14(4): 378 - 386. [Abstract] [PDF]

				B. J. Goldstein and P. J Goodnick Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics J Psychopharmacol, January 1, 1998; 12(4_suppl): 55 - S87. [Abstract] [PDF]

				D. J. Nutt Venlafaxine: the yin and yang of antidepressants? J Psychopharmacol, January 1, 1995; 9(3): 205 - 206. [PDF]